Ranks have swelled between 2010 and 2017 partly because of access to online learning.
The first FDA-approved product for NASH on the horizon.
A new class of drugs for high cholesterol and a novel peanut allergy treatment lead expected approvals.
How pharmacies should adopt value- and performance-based payment models and offer DIR fee reductions for pharmacists’ and their patients’ benefit.
A report card of healthcare indicators shows troubling developments.
Although commenting on the Proposed Rule is closed, if finalized, the Proposed Rule would have a significant impact on the way hospitals and physicians structure future compensation arrangements.
In first year of operation, CareMount ACO physicians reduced costs while improving care.
Having trouble viewing? Click to download
If you are unable to download this pdf file, please try again in another browser.
New plan from CVS Caremark eliminates member cost as a barrier to medications without raising costs for benefits, premiums or deductibles.